Marianne De Backer talks about joining Vir Biotechnology and shares her vision for the future
Vir's new CEO gives an overview of the company's programs including COVID, flu, hepatitis B and delta, and HIV, and discusses future plans to expand into autoimmune disease and oncology.
Comments